shortagewatch

Home / Cancer and immune system / Doxorubicin

ATC L01DB01 · Antineoplastic Agents

Doxorubicin shortage

As of 31 Oct 2026, Doxorubicin has a reported shortage in 4 of the 5 countries we track (Germany, Italy, Austria, Belgium), covering 16 products.

Countries4/5
Products16packs or presentations
Short since31 Aug 20233.2 years ago
Earliest return9 Nov 2026company estimate
No return date10products
Main reasonManufacturing problem

Timeline

GermanyItalyAustriaBelgium
202420252026DOXO-cell 50 mg InjektionslösungDOXO-cell 50 mg InjektionslösungDOXO-cell 150 mg InjektionslösungDOXO-cell 150 mg InjektionslösungDoxorubicinhydrochlorid Bendalis 2 mg/mlDoxorubicinhydrochlorid Bendalis 2 mg/mlDOXORUBICINA ACCORD HEALTHCARE ITALIADOXORUBICINA ACCORD HEALTHCARE ITALIAZOLSKETIL PEGYLATED LIPOSOMALZOLSKETIL PEGYLATED LIPOSOMALCAELYX PEGYLATED LIPOSOMALCAELYX PEGYLATED LIPOSOMALCAELYX PEGYLATED LIPOSOMALCAELYX PEGYLATED LIPOSOMALDOXORUBICINA ACCORD HEALTHCARE ITALIADOXORUBICINA ACCORD HEALTHCARE ITALIADOXORUBICINA ACCORD HEALTHCARE ITALIADOXORUBICINA ACCORD HEALTHCARE ITALIADOXORUBICINA AUROBINDODOXORUBICINA AUROBINDOADRIBLASTINAADRIBLASTINACaelyx 2 mg/ml Konzentrat zur Herstellung eiCaelyx 2 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 1 StückCaelyx Pegylated Liposomal 2 mg/ml inf. sol.Caelyx Pegylated Liposomal 2 mg/ml inf. sol. (conc.) i.v. vial 10 mlDoxorubicin Accord Healthcare 2 mg/ml inf. sDoxorubicin Accord Healthcare 2 mg/ml inf. sol. (conc.) i.v. vial 100 mltoday

Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.

Affected products

CountryProductHolderSinceExpected backReason
DEDOXO-cell 50 mg InjektionslösungSTADAPHARM GmbH16 Aug 202419 Jan 2027Manufacturing problem
Probleme in der Herstellung
DEDOXO-cell 150 mg InjektionslösungSTADAPHARM GmbH16 Sep 202419 Jan 2027Manufacturing problem
Probleme in der Herstellung
DEDoxorubicinhydrochlorid Bendalis 2 mg/mlBENDALIS GmbH15 Nov 202431 Dec 2026Manufacturing problem
Probleme in der Herstellung
ITDOXORUBICINA ACCORD HEALTHCARE ITALIAACCORD HEALTHCARE, S.L.U.31 Aug 2023not givenIncreased demand
Elevata richiesta
ITZOLSKETIL PEGYLATED LIPOSOMALACCORD HEALTHCARE, S.L.U.27 Feb 2025not givenManufacturing problem
Problemi produttivi
ITCAELYX PEGYLATED LIPOSOMALBAXTER HOLDING BV8 Jun 2026not givenManufacturing problem
Problemi produttivi: distribuzione contingentata
ITCAELYX PEGYLATED LIPOSOMALBAXTER HOLDING BV8 Jun 2026not givenManufacturing problem
Problemi produttivi: distribuzione contingentata
ITDOXORUBICINA ACCORD HEALTHCARE ITALIAACCORD HEALTHCARE, S.L.U.30 Sep 2026not givenCommercial decision or withdrawal
Motivi commerciali
ITDOXORUBICINA ACCORD HEALTHCARE ITALIAACCORD HEALTHCARE, S.L.U.1 Oct 2026not givenCommercial decision or withdrawal
Motivi commerciali
ITDOXORUBICINA AUROBINDOEugia Pharma (Malta) Limited9 Oct 2026not givenIncreased demand
Elevata richiesta/problemi produttivi
ITADRIBLASTINAPFIZER ITALIA S.R.L.27 Oct 2026not givenManufacturing problem
Problemi produttivi
ITADRIBLASTINA announcedPFIZER ITALIA S.R.L.10 Nov 2026not givenManufacturing problem
Problemi produttivi
ITADRIBLASTINA announcedPFIZER ITALIA S.R.L.19 Jan 2027not givenManufacturing problem
Problemi produttivi
ATCaelyx 2 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 1 Stück limitedBaxter Holding B.V.9 Sep 202631 Dec 2026Quality problem or recall
Qualitätsprobleme bei der Herstellung
BECaelyx Pegylated Liposomal 2 mg/ml inf. sol. (conc.) i.v. vial 10 mlBaxter Holding19 Aug 20269 Nov 2026Manufacturing problem
Delay in the release of the end product
BEDoxorubicin Accord Healthcare 2 mg/ml inf. sol. (conc.) i.v. vial 100 mlAccord Healthcare14 Oct 202630 Nov 2026Manufacturing problem
Delay in production

"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.

Related medicines also in short supply